Document Detail


Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation.
MedLine Citation:
PMID:  12015790     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The relative lung and systemic bioavailability of sodium cromoglycate following inhalation by different methods have been determined using a urinary excretion pharmacokinetic method. On three separate randomised study days, 7 days apart, subjects inhaled (i) 4x5 mg from an Intal metered dose inhaler (MDI), (ii) 4x5 mg from an MDI attached to a large volume spacer (MDI+SP) and (iii) 20 mg from an Intal Spinhaler (DPI). Urine samples were provided at 0, 0.5, 1, 2, 5 and 24 h post dose. The mean (S.D.) amount of sodium cromoglycate excreted in the urine during the first 30 min post inhalation was 38.1 (27.5), 222.3 (120.3) and 133.1 (92.2) microg following MDI, MDI+SP and DPI, respectively. The mean ratio (90% confidence interval) of these amounts excreted in the urine over the first 30 min for MDI+SP vs. MDI, DPI vs. MDI and MDI+SP vs. DPI was 801.0 (358.0, 1244; p<0.002)%, 457.0 (244.0, 670.0; p<0.02)% and 262.4 (110.2, 414.5)%, respectively. Similarly for the 24 h cumulative amount of sodium cromoglycate excreted over the 24 h post inhalation the ratios were 375.4 (232.9, 517.9; p<0.005)%, 287.5 (183.4, 391.6; p<0.02)% and 211.4 (88.3, 334.5)%, respectively. The results highlight better lung deposition of sodium cromoglycate from a metered dose inhaler attached to a large volume spacer.
Authors:
Osama Aswania; Henry Chrystyn
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Biopharmaceutics & drug disposition     Volume:  23     ISSN:  0142-2782     ISO Abbreviation:  Biopharm Drug Dispos     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-05-23     Completed Date:  2002-07-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7911226     Medline TA:  Biopharm Drug Dispos     Country:  England    
Other Details:
Languages:  eng     Pagination:  159-63     Citation Subset:  IM    
Copyright Information:
Copyright 2002 John Wiley & Sons, Ltd.
Affiliation:
School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Anti-Asthmatic Agents / administration & dosage,  pharmacokinetics*,  urine
Biological Availability
Cromolyn Sodium / administration & dosage,  pharmacokinetics*,  urine
Dose-Response Relationship, Drug
Female
Humans
Lung / metabolism*
Male
Time Factors
Chemical
Reg. No./Substance:
0/Anti-Asthmatic Agents; 15826-37-6/Cromolyn Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified re...
Next Document:  On the assessment of effects of food on the pharmacokinetics of drugs in early development.